VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical
trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least
one menopausal vaginal symptom, vaginal pH > 5.0 and > 20% parabasal vaginal epithelial
cells.